Neovacs: The nominal value of the share is reduced from 1 euro to 0.10 euro

(Boursier.com) — Neovacs a biopharmaceutical company at a preclinical stage developing new therapies for inflammatory and autoimmune diseases, announces that the Board of Directors, on the basis of the 8th resolution voted at the General Meeting of June 30, 2023, has decided to carry out a capital reduction motivated by losses by reducing the par value of the company’s shares.
The par value of the share is reduced from 1 euro to 0.10 euro. The company’s share capital, divided into 397,097 shares, was reduced from 397,097.00 euros to 39,709.70 euros.